Semaglutide weight loss outcomes in clinical trials
| Trial | Population | Mean Wt Loss | Duration | ≥5% Loss |
|---|---|---|---|---|
| STEP 1 | Obesity, no T2D (N=1,961) | 14.9% | 68 wk | 86.4% |
| STEP 5 | Obesity, no T2D (2-year) | 15.2% | 104 wk | 77.1% |
| STEP 2 | Obesity + T2D | 9.6% | 68 wk | 68.8% |
| STEP TEENS | Adolescents, BMI reduction | 16.1% BMI | 68 wk | 73% |
STEP 1 (N=1,961, adults with obesity, no type 2 diabetes, 68 weeks): mean body-weight reduction 14.9% with semaglutide 2.4 mg weekly versus 2.4% with placebo. 86.4% of semaglutide participants achieved ≥5% weight loss versus 31.5% with placebo; 50.5% achieved ≥15% versus 4.9%.[1]
STEP 5 (104 weeks, two-year data): 15.2% mean weight reduction sustained; 52.1% achieving ≥15% and 36.1% achieving ≥20% reduction. 77.1% achieving ≥5% versus 34.4% placebo.[2]
STEP 2 (adults with type 2 diabetes): 9.6% mean weight reduction at 68 weeks versus 3.4% placebo. HbA1c improved by 1.6 percentage points. 68.8% achieved ≥5% weight loss versus 28.5% placebo.[5] The lower weight-loss magnitude versus STEP 1 (obesity-only population) is consistent with the known metabolic resistance in type 2 diabetes patients.
STEP TEENS (N=201, adolescents ages 12–17, 68 weeks): BMI reduction 16.1% versus 0.6% increase with placebo. 73% of semaglutide participants achieved ≥5% BMI reduction versus 18% placebo. Additional improvements: waist circumference, triglycerides (-28.4%), total cholesterol, alanine aminotransferase.[16] GI adverse events 62% versus 42% placebo.
Can you lose weight on Semaglutide?
STEP 1 trial (2021, NEJM) reported mean 14.9% body weight reduction at 68 weeks with 2.4 mg weekly semaglutide versus 2.4% with placebo in adults with obesity — statistically significant across all pre-specified endpoints.[1]
How much weight can you lose on Semaglutide?
STEP 1 (N=1,961): mean 14.9% at 68 weeks; STEP 5 (two-year data): 15.2% sustained. Individual response varied — roughly 50.5% of participants in STEP 1 achieved ≥15% weight loss, and 36.1% achieved ≥20% in the STEP 5 two-year cohort.[1] [2]
Mechanisms underlying Semaglutide-induced weight reduction
Weight reduction operates through at least three concurrent mechanisms: CNS appetite suppression via GLP-1 receptor activation in the hypothalamic arcuate nucleus (POMC/CART neuronal activation, NPY/AgRP inhibition), delayed gastric emptying reducing meal-time caloric intake, and potential direct effects on adipose tissue metabolism — including adipose browning via PGC-1alpha/PRDM16/UCP1 upregulation documented in 2024 mechanistic review data.[11]
The combination produces a sustained caloric deficit in research subjects without requiring conscious dietary restriction as the primary mechanism. GLP-1 receptor agonism shifts the set-point of appetite signaling rather than requiring willpower-mediated restraint.
How does Semaglutide work for weight loss?
Primarily through CNS appetite suppression (GLP-1 receptor activation in hypothalamic arcuate nucleus and brainstem), delayed gastric emptying reducing meal-time caloric intake, and potential direct effects on lipid metabolism — collectively producing a sustained caloric deficit in research subjects.[11] [12]
How long does it take for Semaglutide to work?
Phase 3 trials show measurable body weight reductions at week 4 (initial dose phase), with peak efficacy observed between weeks 52–68 at the 2.4 mg maintenance dose; glycemic effects appear earlier (weeks 2–4 in SUSTAIN-1[1]).
Body composition changes in Semaglutide research
STEP 1 DEXA substudy (N=140): fat mass decreased 19.3% total; visceral adipose tissue decreased 27.4%. Absolute lean body mass also decreased — 9.7% over 68 weeks. The lean-to-fat mass ratio improved by 0.23 overall — more fat than lean mass was lost per unit of total weight lost.[15]
Visceral adipose tissue — the metabolically active fat stored around abdominal organs — declined 27.4%, proportionally greater than total fat mass reduction. This is the component most associated with cardiovascular and metabolic risk.
Participants achieving ≥15% total weight loss showed a 0.41 improvement in lean-to-fat ratio. Trials incorporating resistance exercise co-intervention showed attenuated lean mass loss, but direct isolation of semaglutide's effect on muscle protein synthesis has not been performed.
Will Semaglutide reduce belly fat?
Imaging substudies of STEP 1 show visceral adipose tissue reductions of 27.4% alongside 19.3% total fat mass reduction; absolute lean body mass also decreases, and the ratio of fat-to-lean loss varies by baseline muscle mass and exercise co-intervention in study arms.[15]
Onset of Semaglutide effects in study populations
Body weight reductions were statistically detectable at week 4 in STEP 1, during the initial low-dose escalation phase (0.25 mg). Peak efficacy at the 2.4 mg maintenance dose was observed between weeks 52–68 — the plateau in mean weight loss visible in STEP 1 and STEP 5 trial curves. Glycemic effects (postprandial glucose reduction) appear within 24–48 hours of first dose in pharmacokinetic studies; HbA1c improvements documented at weeks 2–4 in SUSTAIN-1 data.[1]
Steady-state plasma concentrations require 4–5 weeks to achieve with once-weekly dosing.[10] The full pharmacodynamic effect is therefore not reached until after the 4–5 week pharmacokinetic equilibration period overlaps with the final maintenance dose — explaining why peak weight loss magnitude is not observed until weeks 52–68 in the trial data.
When does Semaglutide start working?
Pharmacodynamic effects are measurable within 24–48 hours of first dose (postprandial glucose reduction); body weight changes statistically detectable at week 4 in STEP 1; clinically meaningful weight loss (≥5%) first observed at median week 16–20 in trial populations.[1]